Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African Adults
This study has been suspended.
( Based on an interim data review, the DSMB concluded that the vaccine cannot be shown in this trial to prevent HIV infection or affect the course of the disease. )
Study NCT00413725
Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: December 18, 2006
Last Updated: May 16, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
